HSP70-IN-6
HSP70-IN-6 (JL-15) is an inhibitor of Hsp70-Bim protein-protein interaction, with an IC50 value of 0.07 μM against Hsp70-Bim PPI, an IC50 of 4.89 μM and a Kd of 0.123 μM for BimBH3-stimulated Hsp70 ATPase activity. HSP70-IN-6 selectively blocks the binding of Hsp70-Bim without affecting the Hsp70-Bag3 interaction, and inhibits BimBH3-stimulated Hsp70 ATPase activity but has no impact on basal ATPase activity. HSP70-IN-6 induces apoptosis (apoptosis) in chronic myeloid leukemia cells in an Hsp70-Bim-dependent manner. HSP70-IN-6 can be used in research related to chronic myeloid leukemia.
For research use only. We do not sell to patients.
- CAS No.: 3048341-44-9
- Formula: C28H30ClN3O2
- Molecular Weight:476.01
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
|
HSP70 |
Bim |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BV-173 | EC50 |
0.43 μM
Compound: 22; JL-15
|
Induction of apoptosis in human BV-173 cells incubated for 48 hrs by Annexin V-FITC staining based flow cytometry analysis
Induction of apoptosis in human BV-173 cells incubated for 48 hrs by Annexin V-FITC staining based flow cytometry analysis
|
[PMID: 39012838] |
| K562 | EC50 |
0.88 μM
Compound: 22; JL-15
|
Induction of apoptosis in human K562 cells incubated for 48 hrs by Annexin V-FITC staining based flow cytometry analysis
Induction of apoptosis in human K562 cells incubated for 48 hrs by Annexin V-FITC staining based flow cytometry analysis
|
[PMID: 39012838] |
In Vitro
HSP70-IN-6 (JL-15) (10 min) potently disrupts the Hsp70-Bim protein-protein interaction in a cell-free fluorescence polarization assay, with an IC50 of 0.07 μM[1].
HSP70-IN-6 (JL-15) (0-50 μM; 30 min preincubation, 10 min luciferin incubation) dose-dependently suppresses BimBH3-stimulated ATPase activity of Hsp70 in a cell-free assay, with an IC50 of 4.89 μM, without affecting basal ATPase activity[1].
HSP70-IN-6 (JL-15) (0.2 mM) directly binds to recombinant Hsp70 in a cell-free ITC assay, with a Kd of 123 nM[1].
HSP70-IN-6 (compound 22) (200 μM; 2:1 compound-to-protein molar ratio) binds to the NBD domain of Hsc70 (highly homologous to Hsp70) within the same hydrophobic cleft targeted by the Hsp70-Bim interaction, as confirmed by H-15N TROSY-HSQC NMR[1].
HSP70-IN-6 (JL-15) (0.5-3.0 μM; 12 h) dose-dependently and selectively disrupts the Hsp70-Bim protein-protein interaction in K562 CML cells, without affecting the Hsp70-Bag3 complex[1].
HSP70-IN-6 (JL-15) (10 mg/mL; 24 h) has a water solubility of 29.42 μg/mL, representing a 4-fold improvement over the reference compound S1g-10[1].
HSP70-IN-6 (JL-15) (48 h) potently induces apoptosis in TKI-sensitive (BV173, K562) and TKI-resistant (K562-R3) CML cell lines with sub-μM EC50 values, while exhibiting no significant toxicity to normal HEK293 and BaF3 cells[1].
HSP70-IN-6 (JL-15) (2 μM; 24 h)-induced apoptosis in K562 CML cells is dependent on the presence of Hsp70 and Bim, confirming on-target activity[1].
HSP70-IN-6 (JL-15) (2 μM; 12 h) reduces the expression levels of oncogenic client proteins AKT, Raf-1, and eIF4E in K562 CML cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:K562 CML cells
-
Concentration:2 μM
-
Incubation Time:12 h and 24 h
-
Result:Significantly decreased the expression levels of AKT, Raf-1, and eIF4E in K562 cells.
Upon shRNA knockdown of either Hsp70 or Bim in K562 cells, significantly resisted JL-15-induced PARP cleavage, confirming the on-target effect in living cells.
-
Cell Line:K562 CML cells
-
Concentration:0, 0.5, 1.0, 3.0 μM
-
Incubation Time:12 h
-
Result:Upon treatment with gradient concentrations (0, 0.5, 1.0, and 3.0 μM) for 12 h in K562 cells, dose-dependently and selectively disrupted the Hsp70-Bim protein-protein interaction, without significantly affecting the Hsp70-Bag3 complex.
Chemical Information
-
CAS No. 3048341-44-9
-
Molecular Weight 476.01
-
Formula C28H30ClN3O2
-
SMILES
OC1=C(C(NCCN2CCCCC2)=CC(C3=CC=C(C=C3)OC4=CC(C)=C(C(C)=C4)Cl)=C1)C#N
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Pull-down
The pull-down assay is an in vitro technique used to detect physical interactions between two or more proteins and an invaluable tool for confirming a predicted protein-protein interaction or identifying novel interacting partners. This method typically involves the use of affinity purification with various wash and elution steps.
-
Immunoprecipitation
Immunoprecipitation (IP) is an experimental method that uses the principle of antibody specific binding to purify and enrich target proteins.
-
Protocol for Bimolecular Fluorescence Complementation (BiFC) Assay
Bimolecular fluorescence complementation detects protein-protein proximity in living or fixed cells by fusing two candidate interaction partners to nonfluorescent N- and C-terminal fragments of a fluorescent protein; when the partners interact or remain close enough, the fluorescent fragments complement, mature, and generate a fluorescent signal at the site of the protein complex. The BiFC readout is fluorescence intensity and subcellular localization of the reconstituted fluorophore, which reflects formation or stabilization of a protein complex rather than direct biochemical binding kinetics; BiFC is therefore useful for mapping where interactions occur in cancer cells, neurons, macrophages, organoid-derived cells, or drug-screening systems, but results should be validated by independent assays such as co-IP or Western blot. BiFC signal formation is delayed by fluorophore maturation and can stabilize otherwise transient complexes, so it is not a real-time reversible interaction assay
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Co-Immunoprecipitation
Co-immunoprecipitation technology can verify protein interaction based on the specific immune reaction between antibodies and antigens.
-
Protocol for Yeast Two-Hybrid (Y2H) Assay
The yeast two-hybrid assay detects binary protein-protein interactions by separating a transcription factor into a DNA-binding domain fused to a "bait" protein and a transcriptional activation domain fused to a "prey" protein; if bait and prey interact in yeast, the transcription factor is reconstituted and activates reporter genes such as HIS3, ADE2, lacZ, MEL1, or other selectable/readable reporters. The readout is yeast growth on selective medium and/or reporter activity, which reflects proximity-dependent transcriptional activation in the yeast nucleus rather than direct biochemical binding in the original mammalian, tumor, neuronal, macrophage, or organoid context. Because yeast two-hybrid can generate false positives and false negatives, interaction claims should be validated using independent assays such as co-immunoprecipitation, Western blot, immunofluorescence colocalization, BiFC, pull-down, or mammalian two-hybrid assays.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)